Regional Dynamics
Regional segmentation of the
global Hepatocellular
Carcinoma Drugs Market by Coherent Market Insights comprises North America,
Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is
expected to hold a dominant position in the global hepatocellular carcinoma
drugs market over the forecast period, owing to increasing prevalence of the
disease and the rising number of clinical trials undertaken by the
manufacturers to address the unmet medical needs of the patients. According to
the survey by the Health Science Department, University of California, Los
Angeles, (UCLA), 2017, hepatocellular carcinoma (HCC) accounts for three
quarters of liver cancers in the U.S. with an estimated 40,000 Americans
diagnosed with liver cancer in 2017 and more than 28,000 deaths are reported
from the disease. Also, in April 2018, Eli Lilly and Company completed Phase 3
research study of Cyramza (ramucirumab) as a single agent in the second-line
treatment of people with hepatocellular carcinoma, also known as liver cancer.
Asia Pacific is expected to gain
significant traction in the global hepatocellular carcinoma drugs market owing
to rising number of research and development activities undertaken by the
manufacturers in the region to develop effective therapies. For instance, in
February 2017, Daiichi Sankyo, a pharmaceutical company in Japan completed the
Phase-3 study of tivantinib indicated for patients with hepatocellular
carcinoma treated with other therapies.
Hepatocellular carcinoma (HCC) is
a major type of primary liver cancer that arises from the liver cells or
hepatocytes. The disease is found to occur mainly in patients with hepatitis B,
hepatitis C, cirrhosis, obesity, and diabetes. Diagnosis of hepatocellular
carcinoma is mainly done by imaging tests such as ultrasound, MRI, CT scan, and
liver biopsy. Treatment for hepatocellular carcinoma mainly includes radiation
therapy, ablation therapy in addition to chemotherapy and targeted drug
therapy. A majority of the HCC patients are diagnosed at the end-stage of liver
dysfunction. Due to poor prognosis of the condition, mortality rate is
approximately the same as the incidence rate. Therefore, early detection of the
cancer is an important parameter to improve the survival of affected patients,
thus aiding in growth of the global hepatocellular carcinoma drugs market.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/1596
Market Dynamics
Increasing incidence of global
hepatocellular carcinoma cases is a major factor augmenting market growth.
According to the research by International Journal of Cancer Research and
Treatment, 2014, HCC is the sixth most common type of cancer worldwide and
third most common cause of death worldwide, fifth for men and eighth for women.
The disease accounts for more than 5% of all cancers and for 80-90% of primary
liver cancers. Also, according to the Addis Ababa University, 2017,
hepatocellular carcinoma (HCC) accounted to 854,000 new cases of liver cancer
and 810,000 related deaths in 2015. Furthermore, increasing incidence and
mortality of hepatocellular carcinoma is attributed to the emergence of new
risk factors such as hepatitis B and C viral infections, metabolic disorders
such as diabetes and non-alcoholic fatty liver disease, and exposure to toxins
such as alcohol and aflatoxin.
Moreover, clinical advancements
integrated with the approval of novel drugs by the regulatory agencies for
treating hepatocellular carcinoma is augmenting growth of the market. For
instance, in April 2017, the U.S. Food & Drug Administration expanded the
indications of regorafenib (Stivarga) manufactured by Bayer HealthCare
Pharmaceuticals Inc., for treatment of patients with hepatocellular carcinoma.
The therapy showed significant improvement in survival for patients after the
failure of standard treatments. Also, in 2017, the U.S. FDA granted accelerated
approval for nivolumab (Opdivo) drug developed by Bristol-Myers Squibb for the
treatment of hepatocellular carcinoma.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/hepatocellular-carcinoma-drugs-market-1596
However, the side effects
associated with the drugs such as anemia, constipation, low white blood cell
count, pneumonia are the factors restraining growth of the market.
Competitive Analysis
The manufactures are focused on
strategic collaborations to jointly develop and commercialize immunotherapies indicated
to treat broad range of tumors. For instance, in 2014, Bristol-Myers Squibb
Company and Ono Pharmaceutical Co., Ltd. signed a strategic collaboration
agreement to jointly develop and commercialize multiple immunotherapies as
single agents and combination therapies with Opdivo, to help address the unmet
medical needs of patients with cancer in Japan, South Korea and Taiwan. Also,
in 2015, Novartis Pharmaceuticals initiated the Phase 2 trials to compare the
safety and efficacy for dovitinib and sorafenib in adult patients with advanced
hepatocellular carcinoma.
Key players operating in the
global hepatocellular carcinoma drugs market include Novartis Pharmaceuticals,
Bayer AG, Merck & Co., Inc., Bristol-Myers Squibb Company, AbbVie Inc.,
Johnson & Johnson, Celgen Corporation, Amgen Inc., Teva Pharmaceutical
Industries Ltd., Pfizer Inc., and Takeda Pharmaceutical Co. Ltd.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/1596
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN
: +050-5539-1737
No comments:
Post a Comment